Novo Nordisk releases earnings and guidance
Novo Nordisk CEO Maziar Mike Doustdar waits for the start of the pharmaceutical company’s annual general meeting in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters U.S.-traded shares of Novo Nordisk dropped more than 5% on Tuesday after the Danish drugmaker released guidance that appeared to disappoint investors. The company hiked its 2026 outlook,…